Preclinical Imaging Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Preclinical Imaging Market Trends and Insights

AI-Augmented Multimodal Imaging: Redefining Research Capabilities

Automated image acquisition and cross-modality analysis powered by artificial intelligence now cut processing times by as much as 70%, freeing scientists to focus on interpretation rather than data wrangling.^{[1]Bruker Corporation, “AI-Enhanced Multimodal Imaging for Translational Research,” bruker.com} The technology enables synchronized anatomical, functional, and molecular readouts within the same animal, boosting statistical power while reducing cohort sizes. Fluorescence microscopy paired with 3T–7T MRI furthers insight into ionic shifts in cardiac and neurologic tissue, demonstrating the preclinical imaging market’s push toward non-invasive, longitudinal observation of disease progression. Commercial platforms embedding AI pipelines also simplify onboarding for less-experienced laboratories, widening the user base and injecting fresh demand into the preclinical imaging market. 

Expansion of Cell & Gene Therapy Pipelines Driving Demand for Longitudinal In-vivo Tracking

Sixteen U.S. approvals for cell and gene therapies through 2024 created ripple effects that permeate discovery and toxicology workflows.^{[2]U.S. Food and Drug Administration, “Approved Cellular and Gene Therapy Products,” fda.gov} Academic hubs such as Stanford’s Center for Cell and Gene Therapy illustrate how reporter gene imaging allows transplanted cells to be followed for months, providing safety and persistence data that regulators require.^{[3]Stanford Medicine, “Reporter Gene Imaging in Cell Therapy,” med.stanford.edu} These needs translate to sustained orders for multimodal scanners capable of sensitive, whole-body tracking, reinforcing long-term growth in the preclinical imaging market. 

Government-Sponsored National Preclinical Imaging Infrastructure Programs

Grant schemes like the U.S. Small Business Innovation Research initiative funnel up to USD 1.8 million into imaging technology development, encouraging start-ups to commercialize innovations that academic budgets alone could not support. Public funds lower the cost barrier for high-field MRI and hybrid PET/SPECT/CT platforms, deepening installed bases and stimulating service revenue across the preclinical imaging market. 

Increase in Preclinical Research Funding from Private and Public Organizations

A GBP 57 (USD 76.7) million award to three U.K. universities in 2024 underscores the global surge of capital targeting advanced imaging, quantum technologies, and med-tech. Complementary micro-grants, such as the USD 5,000 MRI pilot awards issued by Stanford’s Wu Tsai Neurosciences Institute, cultivate a pipeline of novel applications that later mature into commercial demand. More institutions entering the frame multiply usage hours on shared equipment, driving consumables and maintenance revenue within the preclinical imaging market. 

Scarcity of Skilled Operators for Multimodal Systems in Emerging Markets

Hybrid scanners demand cross-training in MRI, PET, optics, and data science, skills rarely found in a single individual. Laboratory downtime arises when qualified staff migrate to higher-paying hubs, constraining capacity expansion. Vendors respond with cloud-based remote operation dashboards that stretch expert support across facilities, yet talent shortages persist, tempering the pace of new installations in parts of Asia, Latin America, and Africa. 

Strict Regulations in Preclinical Research

Revised guidance on animal welfare in the European Union mandates deeper justification for animal numbers, intensifying documentation workload and lengthening study timelines. Projects that cannot integrate advanced imaging to monitor the same animals over time now face increased scrutiny, creating a compliance hurdle for less-equipped sites and restraining pockets of demand in the preclinical imaging market. 

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Modality: Hybrid Platforms Outpace Established Optical Leaders

Optical systems retained 34.78% of the preclinical imaging market in 2025, benefiting from affordability, intuitive operation, and real-time readouts that suit routine oncology and infectious-disease studies. The segment’s installed base remains pivotal for high-throughput screening, yet its CAGR lags emerging alternatives. Hybrid systems, notably PET/SPECT/CT and PET/MR, are forecast to grow 9.43% annually through 2031 as investigators seek multi-parametric insights without multiple anesthetic events. Advanced devices such as the MILABS VECTor integrate functional and anatomical imaging down to 4 µm, expanding experimental design latitude. Revvity’s IVIS SpectrumCT 2 exemplifies the convergence trend by adding CT attenuation correction to optical data, thereby enhancing quantification accuracy and boosting the preclinical imaging market size for hybrid platforms.

Falling component costs and improved workflow automation further accelerate hybrid adoption. Research consortia in Asia and Europe increasingly mandate multimodal capabilities when procuring shared equipment, highlighting the strategic shift from single-modality reliance. These preferences feed recurring demand for service contracts and software upgrades, deepening vendor revenue streams across the preclinical imaging market.

By Application: Oncology Leads but Neurology Surges

Oncology applications generated 39.55% of revenue in 2025, underpinned by continual innovation in immuno-oncology and targeted drug delivery. Chemical exchange saturation transfer (CEST) MRI, nanoparticle-enhanced CT, and optical reporters enable early tumor response assessment, guiding dose selection and accelerating go/no-go decisions. Meanwhile, neurology commands the fastest CAGR of 10.02% to 2031, spurred by aging populations and unmet needs in neurodegenerative disorders. High-field functional MRI paired with magnetic resonance spectroscopy allows researchers to interrogate both structure and metabolism in transgenic mouse models, an advance exemplified by Bruker’s BioSpec Maxwell series.

Cross-fertilization between neurology and cell-based therapeutics is adding further momentum. As gene-editing and regenerative therapies transition from concept to clinic, sponsors leverage longitudinal imaging to track vector biodistribution and graft viability, which expands the preclinical imaging market size tied to neurological indications.

By End User: CROs Capture Momentum from Pharmaceutical Outsourcing

Pharmaceutical and biotechnology enterprises held 44.92% of the preclinical imaging market in 2025 as they continue to anchor significant internal discovery and toxicology work. Nonetheless, CROs grow at an 11.34% CAGR because they provide turnkey multimodal capabilities, certified quality systems, and rapid study initiation. Smaller biotechs opt for external imaging to avoid capital expenditure, while large pharma uses CROs to flex capacity during peak pipelines. This outsourcing wave stimulates sales of scalable systems and cloud-ready analytics dashboards, enriching the preclinical imaging market size served by service providers.

CRO consolidation is also underway. Regional providers merge to achieve critical mass, negotiate better equipment pricing, and offer end-to-end regulatory datasets. The trend convinces equipment vendors to package maintenance and training services, helping CRO clients keep uptime high and maintain compliance without adding staff.

Geography Analysis

North America accounted for 47.62% of the preclinical imaging market in 2025. Federal grants like SBIR and sustained venture capital inflows finance a dense network of academic-industry collaborations. Centers such as MD Anderson Cancer Center house 7 T MRI and tri-modality PET/SPECT/CT systems, underlining the region’s commitment to maintaining technological edge. Breakthroughs such as integrated photoacoustic tomography-MRI workflows have emerged from U.S. labs, enabling concurrent vascular and metabolic imaging that refines tumor characterization.

Asia is the fastest-growing region with a 9.16% CAGR through 2031. China and Japan spearhead investment in sophisticated facilities, while national funding schemes streamline procurement approvals. Hong Kong Polytechnic University’s installation of 7 T MRI and advanced photoacoustic ultrasound reflects the region’s rapid capability build-up. Governments also nurture domestic CROs, offering subsidies that offset high import tariffs on imaging components, expanding regional participation in the preclinical imaging market.

Europe maintains robust share through well-coordinated public-private partnerships. Stringent animal welfare regulations accelerate demand for non-invasive modalities that reduce animal numbers, aligning ethical and scientific priorities. Investment vehicles like Discovery Park Ventures’ stake in Vox Imaging Technology channel fresh capital into MRI miniaturization, ensuring a pipeline of home-grown innovation. Vendors emphasize harmonized software platforms across preclinical and clinical lines: United Imaging’s translational architecture lets data flow seamlessly from rodent to human studies, reinforcing Europe’s focus on clinically predictive imaging workflows.

Regulatory Landscape

Preclinical imaging platforms intersect with medical-device rules when systems, accessories, or software are marketed for diagnostic use, or when evidence is generated to support regulated submissions. In the United States, the FDA regulates radiology devices under Title 21 CFR, including magnetic resonance diagnostic devices that commonly follow the 510(k) pathway (for example, 21 CFR 892.1000). Requirements are anchored in substantial equivalence, labeling, and quality-system expectations, and preclinical study data used in submissions is also shaped by Good Laboratory Practice principles for preclinical work.

In Europe, manufacturers operating under the EU Medical Devices Regulation (MDR 2017/745) must maintain comprehensive technical documentation and demonstrate conformity with the General Safety and Performance Requirements (GSPR), which increases the emphasis on documented preclinical evaluation. Commission Delegated Regulation (EU) 2026/1451 (dated 20 March 2026) amends elements tied to clinical investigation exemptions for certain device categories, while keeping broader clinical evaluation obligations in place. For higher-risk devices, the EMA expert panel scientific advice mechanism has moved from pilot to an established program (pilot submissions ended 30 June 2024), offering an additional route for sponsors to align evidence plans for high-risk medical devices where imaging performance and validation datasets are central.

Market Opportunities and Future Outlook

Whitespace driven by technology is emerging across ultra-high-field MRI and photon-counting CT for preclinical translational research, alongside more affordable alternatives that reduce dependence on large centralized PET infrastructure. Bruker commissioning of an 18 Tesla BioSpec preclinical MRI at the Champalimaud Foundation (Portugal) signals continued investment in high-end neuroscience and oncology imaging, while adoption of a MARS color photon-counting CT system at Charles University via the Euro-BioImaging network points to growing European demand for higher-resolution, quantitative in vivo phenotyping.

Service and outsourcing models are also expanding the addressable base for advanced modalities, especially where specialized radiopharmaceutical work depends on dedicated workflows. The April 2026 Perceptive Discovery partnership with MH3D to launch the a-Sight service, built around Alpha-SPECT Mini for direct in vivo imaging of alpha-emitting radiopharmaceuticals, shows how CRO-style differentiation can turn niche modality access into repeatable service revenue. In parallel, academic demonstrations of lower-cost Cherenkov-light imaging using cooled CMOS cameras, along with advances such as photon-counting micro-CT for cardiac phenotyping, are feeding a pipeline of methods that can be productized into smaller-footprint systems and software-first upgrades. These directions also align with buyer constraints around installation cost, operator scarcity, and protocol standardization.